PubRank

Lifeng Cai

Author PubWeight™ 16.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PLoS One 2011 1.08
2 The role of amphiphilicity and negative charge in glycoprotein 41 interactions in the hydrophobic pocket. J Med Chem 2009 0.98
3 Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains. J Virol 2009 0.94
4 Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 2012 0.93
5 Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol 2011 0.93
6 Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library. Bioorg Med Chem Lett 2012 0.89
7 Crystal structure of Pseudomonas aeruginosa Tsi2 reveals a stably folded superhelical antitoxin. J Mol Biol 2012 0.89
8 A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41. Biol Chem 2006 0.89
9 d(TGGGAG) with 5'-nucleobase-attached large hydrophobic groups as potent inhibitors for HIV-1 envelop proteins mediated cell-cell fusion. Bioorg Med Chem Lett 2011 0.80
10 A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. J Biol Chem 2011 0.79
11 Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. Chem Commun (Camb) 2012 0.78
12 Increase of anti-HIV activity of C-peptide fusion inhibitors using a bivalent drug design approach. Bioorg Med Chem Lett 2013 0.78
13 Inter-chain acyl transfer reaction in a peptide six-helical bundle: a chemical method for regulating the interaction between peptides or proteins. Chem Commun (Camb) 2012 0.77
14 Design, synthesis, and biological evaluation of highly potent small molecule-peptide conjugates as new HIV-1 fusion inhibitors. J Med Chem 2013 0.77
15 DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes. Antimicrob Agents Chemother 2013 0.77
16 Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. Bioorg Med Chem Lett 2012 0.77
17 Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. J Med Chem 2014 0.77
18 Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket. Amino Acids 2012 0.75
19 Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. Curr Top Med Chem 2016 0.75
20 Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity. AIDS 2014 0.75
21 [Study of noninvasive measurement of venous pressure]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2002 0.75
22 Calculation of esophageal variceal wall tension by ultrasonic microprobe and noninvasive pressure measurements. Rom J Gastroenterol 2002 0.75
23 Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions. Chem Commun (Camb) 2013 0.75
24 Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold. Chembiochem 2011 0.75
25 Silica nanonetwork confined in nitrogen-doped ordered mesoporous carbon framework for high-performance lithium-ion battery anodes. Nanoscale 2015 0.75